About MiRagen
MiRagen is a company based in Boulder (United States) founded in 2007 by Sanjoy Mahanty, William Marshall, and Bruce Booth. MiRagen has raised $111.29 million across 19 funding rounds from investors including Fidelity Investments, Citadel and Atlas Venture. The company has 92 employees as of December 31, 2022. MiRagen has completed 2 acquisitions, including Signal Genetics and Viridian Bio. MiRagen offers products and services including TED Programs and FcRn Portfolio. MiRagen operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boulder, United States
- Employees 92 as on 31 Dec, 2022
- Founders Sanjoy Mahanty, William Marshall, Bruce Booth
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Miragen Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$111.29 M (USD)
in 19 rounds
-
Latest Funding Round
$91 M (USD), Post-IPO
Oct 28, 2020
-
Investors
Fidelity Investments
& 20 more
-
Employee Count
92
as on Dec 31, 2022
-
Investments & Acquisitions
Signal Genetics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MiRagen
MiRagen offers a comprehensive portfolio of products and services, including TED Programs and FcRn Portfolio.
Develops treatments for thyroid eye disease through antibody engineering.
Focuses on therapies for autoimmune conditions via optimized antibodies.
People of MiRagen
Unlock access to complete
Unlock access to complete
Funding Insights of MiRagen
MiRagen has successfully raised a total of $111.29M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $91 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MiRagen
MiRagen has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for MiRagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MiRagen
MiRagen has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Signal Genetics and Viridian Bio.
Investment portfolio details for MiRagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Providing aid in translating basic science research into products
|
Locked | Locked | 2019 | Locked | |
|
Microarray-based prognostic tests are provided for disease risk assessment.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for MiRagen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MiRagen
Detailed financials for MiRagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Miragen Comparisons
Peer comparison for MiRagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MiRagen
MiRagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of MiRagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Miragen
Complete news archive for MiRagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiRagen
MiRagen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
MiRagen is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
MiRagen is a funded company, having raised a total of $111.29M across 19 funding rounds to date.
As of Dec 31, 2022, the latest employee count at MiRagen is 92.
MiRagen was established in 2007 in Boulder, United States, within the biotechnology sector. MicroRNA-based therapeutic solutions are created for addressing various diseases, including haematological malignancies, neurodegeneration, and ischemia. The drug pipeline features candidates like MRG-106, MRG-107, and MRG-110. Co-founders such as Sanjoy Mahanty, William Marshall, and Bruce Booth contribute to leadership in these operations.
MiRagen's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
MiRagen offers TED Programs and FcRn Portfolio.
MiRagen has made 2 acquisitions, including Signal Genetics, and Viridian Bio.
MiRagen has 21 investors. Key investors include Fidelity Investments, Citadel, Atlas Venture, Perceptive Advisors, and Fairmount Funds Management.